3 gene ther­a­py com­pa­nies se­cure VC mon­ey; No­valis clos­es near­ly $30 mil­lion fund

A Eu­ro­pean life sci­ences VC firm will in­vest in three more star­tups spe­cial­iz­ing in rare ge­net­ic dis­eases as a part of its Sofinno­va Telethon Fund …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.